Drug manufacturers and healthcare providers offer the most upside.
Both Bristol-Myers Squibb and Pfizer are well-positioned for growth.
The continued strong data in multiple cancers reinforces the strength of Keytruda across multiple indications.
The wide-moat firm's core drug distribution business posted gains of 6% in results that were largely in line with expectations.
The wide-moat drugmaker's lower than expected 2019 guidance doesn't dent our view that the firm will be bolstered by an improving pipeline.
We continue to view the stock as undervalued after total sales matched expectations.
Earnings were mostly in line with our expectations, and we're maintaining our fair value estimate.
The wide-moat firm was leg by its drug unit, but increasing generic pressures weigh on the 2019 outlook.
We don't expect any major changes to our fair value estimate based on the deal, with the expected revenue from acquired cancer drugs offsetting the purchase price and increased R&D expenditures.
We expect appeals to delay any impact but revoking the ACA would likely create the most pressure for the healthcare services companies.
We think the pullback in the stock puts the shares near our fair value estimate and think the long-term implications on the price will not be significant after litigation.
While we believe the restructuring makes strategic sense, the related one-time costs are higher than we expected.
The sale of noncore consumer assets should allow the firm to focus on other consumer products while the purchase of Tesaro improves its standing in the PARP oncology setting.
Damien Conover expects to see fewer major changes to U.S. healthcare policy, and he offers some picks for investors.
Pfizer won't be able to access the U.S. market with its biosimilar version until late 2023, providing AbbVie with additional years of exclusivity and strong cash flows.
The wide-moat firm's results were better than consensus, and we view the stock as slightly overvalued.
We view the company as slightly overvalued but don't expect any major changes to our fair value estimate.
Cost-saving plans and product launches should offset patent losses and drive growth.
We think that Albert Bourla will continue the wide-moat firm's current strategic focus.
A focus on unmet medical needs is helping pharma firms maintain their competitive advantage.
Innovation, clearing regulatory picture, corporate restructurings, and capital redeployment should continue for healthcare stocks in the fourth quarter.
Thanks to strong rare-disease drug data, we've edged up our fair value estimate on the drugmaker.
The market reaction to glyphosate's legal issues looks overdone.
Litigation concerns about glyphosate weedkillers are weighing on Bayer's shares, but we don't expect to make a significant change to our fair value estimate.
The company's entrenched products and developing pipeline are underappreciated.
Growth should moderate amid competition, but we view the stock as fairly valued today.
We don't expect any major changes to our fair value estimate after results were in line with expectations.
The negative news puts increased pressure on AbbVie's remaining pipeline to offset upcoming biosimilar pressures on its key drug Humira.
Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the second quarter.
We like Pfizer, Roche, Allergan, and Medtronic in this space.
The wide-moat firm is going through a paradigm shift, but it is well-positioned for growth.
The company's board is considering a sale or merger, which would maximize shareholder value and draw out the firm's full potential.
We expect the wide-moat drugmaker to take more share from Bristol, Roche, and AstraZeneca based on cross-trial comparisons that support Keytruda over competitive drugs.
We still see value in large-cap pharmaceutical and biotech firms despite Trump's plan to lower drug prices.
The pricing power of branded drugs in the U.S. still looks strong.
The two pharmaceutical giants are trading down due to the short-term miss, but their pipelines and pricing power look good.
The market doesn't fully appreciate the wide-moat drugmaker's long-term potential.
The wide-moat firm was buoyed by new drugs and expense controls, but we're not changing our fair value estimate.
We are increasing our fair value estimate after better that expected earnings but see the stock as fairly valued today.
New products in the pipeline can help the pharma firm continue to raise its payout.
Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the first- quarter.
4- and 5-star stocks are harder to come by in today's market, but a few values are still out there.
The firm’s exit from the process to buy Pfizer’s consumer healthcare business should relive dividend cut concerns.
Mixed phase 2 data for Rova-T has rocked the narrow-moat firm's stock price, but the data doesn't end the potential of the drug, only likely delays its pathway to approval.
The wide-moat drugmaker's cardiovascular drug, Praluent, which it has developed with Regeneron, enjoyed favorable results in a study.
Eli Lilly and Pfizer are well-positioned to bring out drugs with exceptional pricing power.
To achieve faster growth, the wide-moat pharmaceutical firm needs to improve its pipeline prospects.
We're raising our fair value estimate for the wide-moat firm after results ahead of both our expectations.
The overpayment to enter the increasingly competitive hemophilia market is relatively small compared with the overall size of wide-moat Sanofi.8445
Strong top-line Keytruda data reinforces the wide-moat pharma's first mover-advantage in the United States and will help launch the drug in Europe.